Chemotherapy-Induced Myelosuppression Treatment Global Market Report 2024

Chemotherapy-induced myelosuppression treatment involves therapeutic interventions designed to manage and alleviate the suppression of bone marrow activity caused by chemotherapy drugs. The objective of treating chemotherapy-induced myelosuppression is to alleviate symptoms, prevent complications such as infections or bleeding disorders, and support patients in continuing their chemotherapy treatment.

The primary indications for chemotherapy-induced myelosuppression treatment are anemia, neutropenia, and thrombocytopenia. Anemia in this context refers to a condition where the body lacks sufficient healthy red blood cells, leading to fatigue, weakness, and shortness of breath. The various classes of drugs used include growth factors, erythropoietin-stimulating agents, thrombopoietic agents, iron supplements, and others. The market for chemotherapy-induced myelosuppression treatment includes oral and injectable routes of administration, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The chemotherapy-induced myelosuppression treatment market research report is one of a series of new reports that provides chemotherapy-induced myelosuppression treatment market statistics, including chemotherapy-induced myelosuppression treatment industry global market size, regional shares, competitors with a chemotherapy-induced myelosuppression treatment market share, detailed chemotherapy-induced myelosuppression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced myelosuppression treatment industry. This chemotherapy-induced myelosuppression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced myelosuppression treatment market size has grown steadily in recent years. It will grow from $7.65 billion in 2023 to $7.97 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historic period can be credited to the rising need for early diagnosis, the increasing incidence of leukemia, and the heightened focus on research and development.

The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $9.6 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%. The anticipated growth during the forecast period can be attributed to the rising number of cancer patients, increased patient awareness, and the growing adoption of new therapies. Key trends expected in the forecast period include the rise of cost-effective treatments, the adoption of AI algorithm solutions, significant technological advancements, and the introduction of new products and services.

The increasing prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced myelosuppression treatment market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which often invade surrounding tissues and organs, disrupting their normal functions and potentially threatening the individual's overall health and well-being. The rising incidence of cancer can be attributed to exposure to pollution, radiation, certain chemicals, and carcinogens. Chemotherapy-induced myelosuppression treatment is crucial in cancer care for managing the hematological side effects caused by chemotherapy, a standard treatment for various cancer types. For example, in May 2024, the American Society of Clinical Oncology, a US-based professional organization, reported an estimated 20 million new cancer cases in 2022, with projections reaching 35 million new cases globally by 2050. Thus, the increasing prevalence of cancer is fueling the chemotherapy-induced myelosuppression treatment market.

Leading companies in the chemotherapy-induced myelosuppression treatment market focus on developing innovative products, such as myeloprotection therapy, to improve treatment efficacy and patient experience. Myeloprotection therapy involves medical interventions designed to protect the bone marrow and hematopoietic stem cells from damage caused by treatments such as chemotherapy and radiation therapy. For instance, in February 2021, G1 Therapeutics Inc., a US-based biopharmaceutical company, launched COSELA (trilaciclib) for injection to reduce the frequency of myelosuppression caused by chemotherapy in adult patients. This product was approved by the Food and Drug Administration (FDA), a US-based federal agency. This innovative approach alleviates common chemotherapy side effects such as neutropenia, anemia, and thrombocytopenia, which often lead to dose reductions or treatment delays. Cosela integrates seamlessly into existing chemotherapy regimens across different cancer types, enhancing patient tolerance and supporting continuous therapy delivery, potentially improving overall treatment outcomes and quality of life.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to expand its portfolio in oncology and biopharmaceuticals by leveraging Seagen's expertise in antibody-drug conjugates and targeted cancer therapies. This move is intended to strengthen Pfizer's position in the oncology market and advance patient treatment options. Seagen Inc. is a US-based company that develops innovative monoclonal antibody-based therapies for chemotherapy-induced myelosuppression.

Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.

North America was the largest region in the chemotherapy-induced myelosuppression treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced myelosuppression treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemotherapy-induced myelosuppression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced myelosuppression treatment market includes revenues earned by entities by providing services such as red blood cell transfusions, platelet transfusions, antibiotic therapy, and supportive care and related erythropoiesis-stimulating agents, antibiotics, colony-stimulating factors (CSFs), diagnostic kits and hydration solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.